EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis

Amy S Paller iD, Lawrence J Green iD, Nanette Silverberg iD, Stephen Stripling iD, Martina Cartwright iD, Carolyn Enloe iD, Nick Wells, Elaine Kearney Kowalewski iD, Tomoko Maeda-Chubachi iD

Pediatric Dermatology · 2024-05 · 41 (3) · 438-444

DOI: 10.1111/pde.15575 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Dermatology, online erschienen am 27.02.2024. Verfasst von Amy S Paller und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Molluscum Contagiosum, Gels. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novan Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Controlling molluscum contagiosum (MC) infections is critical in atopic dermatitis (AD) management. This post hoc analysis assessed the efficacy and safety of berdazimer gel, 10.3% (topical, antiviral, nitric oxide–releasing medication) versus vehicle in MC patients with or without AD.

Methods

Three Phase 3, multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group trials (B‐SIMPLE[ b erdazimer s odium i n m olluscum p atients with le sions]1, −2, −4) enrolled patients 6 months and older with 3–70 mollusca. Berdazimer or vehicle was applied once daily to all MC lesions for 12 weeks. Data from three Phase 3 studies were integrated for subgroup efficacy and safety assessments using several weighted meta‐analysis approaches. Patients with concurrent AD or a history of AD/eczema were categorized as AD+ subgroup (AD− when absent). Primary efficacy endpoint: complete lesion clearance at Week 12. Safety endpoints included adverse events (AEs) through Week 24 and local skin reactions through Week 12.

Results

Of 1598 enrolled patients, 209 (13.1%) were AD+. Baseline mean lesion counts were greater in AD+ (26.4) than AD− (19.3). Complete clearance rates were higher at Week 12 for berdazimer compared with vehicle in AD+ ( n = 209; 35.0% vs. 27.4%; odds ratio [OR], 1.3; 95% CI, 0.7–2.5) and AD− ( n = 1389; 29.1% vs. 18.9%; OR 1.8; 95% CI 1.4–2.4) subgroups. AEs in AD+ were application‐site pain (21.6% with berdazimer vs. 11.9% with vehicle), dermatitis (12.8% vs. 2.4%), and erythema (9.6% vs. 7.1%).

Conclusions

Berdazimer gel showed favorable efficacy regardless of AD status. Berdazimer‐induced erythema may be indistinguishable from AD symptoms or with inflammatory response upon resolution of molluscum.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicMolluscum ContagiosumGelsHumansMaleFemaleChildDouble-Blind MethodChild, PreschoolAdolescentTreatment OutcomeInfantAdultYoung AdultAntiviral Agents

Stichwörter der Autor:innen

atopic dermatitisberdazimermolluscum contagiosumnitric oxidepediatricstopical administration

Substanzen

GelsAntiviral Agents

Autor:innen und Institutionen

  • Department of Dermatology, Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, USA.
  • Department of Dermatology, George Washington University School of Medicine, Washington, DC, USA.
  • Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Pediatric Department, Coastal Pediatric Research, Charleston, South Carolina, USA.
  • Novan, Inc., Durham, North Carolina, USA.
  • Synteract, Hampshire, UK.

ORCID-Profile: Amy S Paller, Lawrence J Green, Nanette Silverberg, Stephen Stripling, Martina Cartwright, Carolyn Enloe, Elaine Kearney Kowalewski, Tomoko Maeda-Chubachi

Förderung

  • Novan Inc

Zitieren

APA

Paller, A. S., Green, L. J., Silverberg, N., Stripling, S., Cartwright, M., Enloe, C., Wells, N., Kowalewski, E. K., & Maeda-Chubachi, T. (2024). Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis. Pediatric Dermatology, 41(3), 438-444. https://doi.org/10.1111/pde.15575

Vancouver

Paller AS, Green LJ, Silverberg N, Stripling S, Cartwright M, Enloe C, et al. Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis. Pediatric Dermatology. 2024;41(3):438-444. doi:10.1111/pde.15575

BibTeX
@article{Paller2024,
  author = {Paller, Amy S and Green, Lawrence J and Silverberg, Nanette and Stripling, Stephen and Cartwright, Martina and Enloe, Carolyn and Wells, Nick and Kowalewski, Elaine Kearney and Maeda-Chubachi, Tomoko},
  title = {Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis},
  journal = {Pediatric Dermatology},
  year = {2024},
  volume = {41},
  number = {3},
  pages = {438--444},
  doi = {10.1111/pde.15575}
}
Kostenlos starten →